Modified docetaxel, cisplatin, and fluorouracil (Mdcf) as a neoadjuvant chemotherapy for non-metastatic esophageal cancer (nmec)

3Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Objective: Perioperative chemotherapy can potentially downstage esophageal cancer, reducing the risk of early systemic dissemination. One recommended neoadjuvant regimen for managing gastroesophageal junction and esophageal cancer is docetaxel, cisplatin, and 5-fluorouracil (DCF). To address the high toxicity profile of DCF, modifications in dosages and treatment intervals have been studied. We integrated a modified DCF regimen (mDCF) into a multimodal treatment approach for non-metastatic esophageal cancer (nMEC). Retrospectively, we sought to describe our community experience of administrating neoadjuvant mDCF to patients with nMEC. Design: Patients diagnosed with nMEC between August 2008 and November 2017 and prescribed mDCF were identified for retrospective review. Outcomes of interest included disease-free survival (DFS), overall survival (OS), and hematologic toxicities. Analyses were performed using SAS 9.4. Results: Thirty patients met inclusion criteria with a median age of 64.9 years; 90% were male. The 2-year and 5-year DFS was 60.8% and 41.7%, respectively, for adenocarcinoma and 71.4% and 71.4% for squamous cell carcinoma (SCC). The 2-year and 5-year OS was 64.9% and 44.5%, respectively, for adenocarcinoma and 71.4% and 71.4% for SCC. Both DFS and OS decreased with increasing disease stage, histology (adenocarcinoma versus squamous), esophageal compared to esophagogastric-junction involvement, and without surgical intervention. Frequent toxicity grades for leukopenia and thrombocytopenia were Grades I and II. Conclusion: Using an mDCF regimen in combination with chemoradiation +/-surgical resection in a community setting appears to have an acceptable toxicity profile as well as DFS and OS outcomes compared to chemotherapeutic regimens reported in other similar studies.

Cite

CITATION STYLE

APA

Onitilo, A. A., Stankowski-Drengler, T. J., Shiyanbola, O., Engel, J., Tanimu, S., Fagbemi, S. O., & Li, Y. H. (2021). Modified docetaxel, cisplatin, and fluorouracil (Mdcf) as a neoadjuvant chemotherapy for non-metastatic esophageal cancer (nmec). Clinical Medicine and Research, 19(2), 64–71. https://doi.org/10.3121/cmr.2021.1573

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free